Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Average Rating of “Moderate Buy” by Brokerages

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has received an average rating of “Moderate Buy” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $12.3333.

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Jones Trading raised Evaxion A/S to a “strong-buy” rating in a research report on Wednesday, October 29th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Evaxion A/S in a report on Monday, October 20th. Lake Street Capital raised their target price on shares of Evaxion A/S from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Finally, Edward Jones started coverage on Evaxion A/S in a research note on Thursday, October 30th. They set a “buy” rating and a $10.00 price target for the company.

Evaxion A/S Stock Performance

Shares of NASDAQ EVAX opened at $3.34 on Monday. Evaxion A/S has a 1 year low of $1.20 and a 1 year high of $12.15. The stock’s 50-day simple moving average is $4.62 and its 200-day simple moving average is $4.58. The firm has a market cap of $27.86 million, a price-to-earnings ratio of -8.56 and a beta of 0.29.

Institutional Investors Weigh In On Evaxion A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Evaxion A/S in the 4th quarter worth approximately $38,000. Wesbanco Bank Inc. acquired a new position in Evaxion A/S in the fourth quarter worth approximately $48,000. Finally, SmartHarvest Portfolios LLC bought a new position in shares of Evaxion A/S in the fourth quarter valued at $72,000. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.